GlassScriptPhysician profile
Laura Neustater
NPI 1255344875
$474.88
in general payments reported to CMS, 2019-2025
10 companies · $13.61 in 2025
The $13.61 reported for 2025 was less than what a typical Developmental - Behavioral Pediatrics provider received nationally (typical 2025 total: $79.84).
See the full distribution for Developmental - Behavioral Pediatrics
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $37.90 · 2021: $124 · 2022: $18.05 · 2023: $36.38 · 2024: $118 · 2025: $13.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $168.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $127.00 | 2019 | |
| Janssen Biotech, INC. | $106.31 | 2021 | |
| Glaxosmithkline, LLC. | $62.55 | 2021-2024 | Bexsero, Rotarix |
| Sanofi Pasteur INC. | $35.54 | 2023-2025 | |
| Cranial Technologies, INC | $34.97 | 2020-2024 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $32.05 | 2024 | Flumist Quadrivalent |
| Merck Sharp & Dohme LLC | $23.68 | 2024 | Vaxneuvance, Gardasil 9, Gardasil |
| Genentech USA, INC. | $20.28 | 2020 | |
| Kaleo, INC. | $18.05 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.45 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Neustater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.